Overview: C-Reactive Protein (CRP) Marker Rapid TestIntroduction: The C-Reactive Protein (CRP) Marker Rapid Test is a diagnostic tool designed to detect CRP levels in serum or whole blood samples, facilitating the screening of inflammation or infection. CRP, an acute-phase protein produced by the liver, is elevated in response to inflammation, infection, or tissue injury, presenting with fever, pain, and severe complications like sepsis, organ dysfunction, or chronic inflammatory diseases if untreated, particularly in immunocompromised or elderly patients. Per the 2023 Infectious Diseases Society of America guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with high sensitivity and specificity, providing a rapid diagnostic option for emergency and outpatient settings. This rapid diagnostic falls under clinical pathology and targets individuals with systemic symptoms like fever or joint pain, addressing the challenge of identifying early inflammatory processes to prevent progression to severe outcomes. With morbidity rates elevated due to uncontrolled inflammation and associated comorbidities, the test supports targeted therapies like antibiotics, anti-inflammatory drugs, or further investigation, and public health efforts by enabling early intervention to reduce sepsis incidence. Its quick turnaround time aids in triaging patients in acute care settings.Other Names: CRP Rapid Test.FDA Status: FDA approved, CLIA certified for clinical pathology, compliant with 2025 standards.Historical Milestone: Introduced in the 2000s by Roche, this test advanced inflammation monitoring, offering a rapid alternative to traditional immunoassays.Purpose: The test screens for CRP to guide inflammation or infection diagnosis, assess disease activity, and inform treatment and monitoring strategies.Test Parameters: Presence of C-Reactive Protein, detected with high specificity to indicate inflammatory activity, with normal serum levels typically less than 10 mg/L, rising significantly in acute conditions.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report fever, pain, or history of inflammatory disease.Specimen: Serum 2-5 mL, Whole Blood 2-5 mL, collected using sterile SST or EDTA tubes, transported within 24 hours to maintain sample viability.Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve protein integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may denature proteins, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on fever, pain, recent infections, or prior inflammatory conditions, as well as any use of anti-inflammatory medications affecting CRP levels.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated inflammation including sepsis, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid hemolysis or contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, hemolysis, or chronic conditions (e.g., rheumatoid arthritis) can affect results. Correlation with erythrocyte sedimentation rate (ESR), white blood cell count, or clinical evaluation is recommended to confirm findings.Clinical Significance: A positive result (elevated CRP) indicates inflammation or infection, necessitating targeted treatment such as antibiotics or further diagnostics. A negative result may require follow-up testing if symptoms persist, especially in early or chronic disease stages.Specialist Consultation: Infectious disease specialists or rheumatologists should be consulted for case management, treatment planning, and coordination with infectious disease control programs.Additional Supporting Tests: ESR, blood culture, procalcitonin, or imaging for confirmation.Test Limitations: The test may produce false positives due to non-infectious inflammation or false negatives in early infection, requiring a comprehensive diagnostic approach that includes clinical correlation and serial testing.References: IDSA Guidelines 2023, Journal of Infectious Diseases 2024, Clinical Chemistry 2025.